DNA-based immunization by in vivo transfection of dendritic cells
- PMID: 8837611
- DOI: 10.1038/nm1096-1122
DNA-based immunization by in vivo transfection of dendritic cells
Abstract
Delivery of antigen in a manner that induces effective, antigen-specific immunity is a critical challenge in vaccine design. Optimal antigen presentation is mediated by professional antigen-presenting cells (APCs) capable of taking up, processing and presenting antigen to T cells in the context of costimulatory signals required for T-cell activation. Developing immunization strategies to optimize antigen presentation by dendritic cells, the most potent APCs, is a rational approach to vaccine design. Here we show that cutaneous genetic immunization with naked DNA results in potent, antigen-specific, cytotoxic T lymphocyte-mediated protective tumor immunity. This method of immunization results in the transfection of skin-derived dendritic cells, which localize in the draining lymph nodes. These observations provide a basis for further development of DNA-based vaccines and demonstrate the feasibility of genetically engineering dendritic cells in vivo.
Similar articles
-
Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.J Exp Med. 1998 Sep 21;188(6):1075-82. doi: 10.1084/jem.188.6.1075. J Exp Med. 1998. PMID: 9743526 Free PMC article.
-
Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.Eur J Cell Biol. 2007 Dec;86(11-12):817-26. doi: 10.1016/j.ejcb.2006.07.002. Epub 2006 Aug 22. Eur J Cell Biol. 2007. PMID: 16928407
-
Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.Int J Cancer. 1999 Nov 12;83(4):532-40. doi: 10.1002/(sici)1097-0215(19991112)83:4<532::aid-ijc16>3.0.co;2-k. Int J Cancer. 1999. PMID: 10508491
-
Improving DNA vaccine potency via modification of professional antigen presenting cells.Curr Opin Mol Ther. 2003 Feb;5(1):20-4. Curr Opin Mol Ther. 2003. PMID: 12669466 Review.
-
Nanoparticle-mediated enhancement of DNA Vaccines: Revolutionizing immunization strategies.Int J Biol Macromol. 2025 Apr;302:140558. doi: 10.1016/j.ijbiomac.2025.140558. Epub 2025 Feb 1. Int J Biol Macromol. 2025. PMID: 39900152 Review.
Cited by
-
Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine.Cancer Immunol Immunother. 2010 Aug;59(8):1259-72. doi: 10.1007/s00262-010-0852-y. Cancer Immunol Immunother. 2010. PMID: 20390417 Free PMC article.
-
GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.PLoS One. 2010 Jun 8;5(6):e11021. doi: 10.1371/journal.pone.0011021. PLoS One. 2010. PMID: 20544035 Free PMC article.
-
Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.J Virol. 2000 Mar;74(6):2620-7. doi: 10.1128/jvi.74.6.2620-2627.2000. J Virol. 2000. PMID: 10684276 Free PMC article.
-
Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer.Ann Surg. 1997 Jul;226(1):1-5. doi: 10.1097/00000658-199707000-00001. Ann Surg. 1997. PMID: 9242331 Free PMC article. Review. No abstract available.
-
A novel cancer therapeutic using thrombospondin 1 in dendritic cells.Mol Ther. 2014 Feb;22(2):292-302. doi: 10.1038/mt.2013.236. Epub 2013 Oct 15. Mol Ther. 2014. PMID: 24127010 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous